002675 Stock Overview
Engages in the manufacture and sale of biochemical APIs, finished dosage forms, nuclide drugs, and healthy products for cardiovascular, antitumor, urology, orthopedics, and other therapeutic areas. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥12.63 |
| 52 Week High | CN¥19.08 |
| 52 Week Low | CN¥11.33 |
| Beta | 0.40 |
| 1 Month Change | -4.32% |
| 3 Month Change | 6.49% |
| 1 Year Change | -31.06% |
| 3 Year Change | -18.31% |
| 5 Year Change | -18.83% |
| Change since IPO | 111.97% |
Recent News & Updates
Recent updates
Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Has A Pretty Healthy Balance Sheet
Aug 23
Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Business Is Yet to Catch Up With Its Share Price
Jul 12News Flash: 7 Analysts Think Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) Earnings Are Under Threat
May 06Yantai Dongcheng Pharmaceutical GroupLtd's (SZSE:002675) Problems Go Beyond Weak Profit
May 05Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?
Mar 15Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark
Feb 27Shareholder Returns
| 002675 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -4.6% | -4.1% | -2.6% |
| 1Y | -31.1% | -17.9% | 9.7% |
Return vs Industry: 002675 underperformed the CN Biotechs industry which returned -17.9% over the past year.
Return vs Market: 002675 underperformed the CN Market which returned 9.7% over the past year.
Price Volatility
| 002675 volatility | |
|---|---|
| 002675 Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 002675 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002675's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 2,333 | Zhi Gang Luo | www.dcb-group.com |
Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical APIs, finished dosage forms, nuclide drugs, and healthy products for cardiovascular, antitumor, urology, orthopedics, and other therapeutic areas. It offers heparin, chondroitin sulphate sodium and calcium, and glucosamine series products, as well as collagen, hyaluronic acid, and cytochrome C. The company also provides nadroparin calcium, hydrocortisone sodium succinate, chorionic gonadotrophin, and menotropins for injection, as well as ambroxol hydrochloride dispersible tablets, jinjunling capsule, metformin hydrochloride and glibenclamide tablets, clemastine fumarate tablets, and wind dispelling itch relieving granule. In addition, it offers Technetium [99Tc] Methylene Diphosphonate Injection; Technetium [99mTc] Tc labeled tracers; 2-[18F]FDG that helps to detect the activity of tumor cells; sodium iodide [131I] oral solution; iodine [125I] seed use to treat internal radiation of various malignant tumors; [14C]Urea capsule; and jiabaolin glucosamine chondroitin sulfate capsule.
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Fundamentals Summary
| 002675 fundamental statistics | |
|---|---|
| Market cap | CN¥10.41b |
| Earnings (TTM) | CN¥90.79m |
| Revenue (TTM) | CN¥2.85b |
114.7x
P/E Ratio3.7x
P/S RatioIs 002675 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002675 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.85b |
| Cost of Revenue | CN¥1.65b |
| Gross Profit | CN¥1.21b |
| Other Expenses | CN¥1.12b |
| Earnings | CN¥90.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 42.29% |
| Net Profit Margin | 3.18% |
| Debt/Equity Ratio | 15.4% |
How did 002675 perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield114%
Payout RatioDoes 002675 pay a reliable dividends?
See 002675 dividend history and benchmarks| Yantai Dongcheng Pharmaceutical GroupLtd dividend dates | |
|---|---|
| Ex Dividend Date | Dec 19 2024 |
| Dividend Pay Date | Dec 19 2024 |
| Days until Ex dividend | 0 days |
| Days until Dividend pay date | 0 days |
Does 002675 pay a reliable dividends?
See 002675 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 22:50 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yanyin Zhu | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |